Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment

Abstract

The objectives of this study were to assess the benefits of 1) mitoxantrone after three years of follow-up and 2) disease-modifying treatment (DMT) after stopping mitoxantrone. A retrospective analysis was performed on 304 patients with active relapsing-remitting (RR) or progressive multiple sclerosis (PMS) who were treated with mitoxantrone. After mitoxantrone therapy, some patients received DMT (interferon-beta or glatiramer acetate) while others did not. The disease course of the two groups was evaluated by the Expanded Disability Status Scale (EDSS) before and after mitoxantrone and then every year for three years. The mean EDSS score at starting mitoxantrone and three years after stopping mitoxantrone respectively, were: 3.3 (1.3) and 3.2 (1.7) for the RRMS patients and 5.9 (1.2) and 6.4 (1.4) for the PMS patients. Before starting mitoxantrone, demographic and clinical parameters of predictive disability were not significantly different between patients who received DMT or not. The variation of EDSS between time of stopping mitoxantrone and three years later was significantly different (+0.9 versus +0.3; P=0.03) for patients with RRMS. We found that mitoxantrone treatment induces stable disease up to two years after discontinuation of mitoxantrone therapy. In the third year, patients without DMT deteriorated. Multiple Sclerosis 2007; 13: 626-631. http://msj.sagepub.com

Keywords

clinical follow-up disease-modifying treatment mitoxantrone

References

Fox ME , Smith PJ Long-term inhibition ofl DNA synthesis and the persistence ofl trapped topoisomerase II complexes in determining the toxicity ofl the antitumor DNA intercalators mAMSA and mitoxantrone. Cancer Res 1990; 50: 5813-18.

Kapuscinski J. , Darzynkiewicz Z. Condensation ofl nucleic acids by intercalating aromatic cations. Proc Natl Acad Sci U S A 1984; 81: 7368-72.

Fidler JM , DeJoy SQ , Smith FR , Gibbons JJ Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived flrom mitoxantrone-treated mice. J Immunol 1986; 136: 2747-54.

Fidler JM , DeJoy SQ , Gibbons JJ Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression ofl B lymphocyte flunction. J Immunol 1986 ; 137: 727-32.

Gbadamosi J. , Buhmann C. , Tessmer W. , Moench A. , Haag F. , Heesen C. Eflflects ofl mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production ofl immunoglobulin, TNF-alpha and IL-10. Eur Neurol 2003; 49: 137-41.

Bellosillo B. , Colomer D. , Pons G. , Gil J. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis ofl B-chronic lymphocytic leukaemia cells. Br J Haematol 1998; 100: 142-46.

Chan A. , Weilbach FX , Toyka KV , Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes ofl multiple sclerosis patients. Clin Exp Immunol 2005; 139: 152-58.

Neuhaus O. , Wiendl H. , Kieseier BC , Archelos JJ , Hemmer B. , Stuve O. et al. Multiple sclerosis: mitoxantrone promotes diflflerential eflflects on immunocompetent cells in vitro. J Neuroimmunol 2005; 168: 128-37.

Edan G. , Miller D. , Clanet M. , Confavreux C. , Lyon-Caen O. , Lubetzki C. et al. Therapeutic eflflect ofl mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study ofl active disease using MRI and clinical criteria. J Neurol NeurosurgPsychiatry 1997; 62: 112-18.

10.

Edan G. , Morrissey S. , Le Page E. Rationale flor the use ofl mitoxantrone in multiple sclerosis. J Neurol Sci 2004; 223: 35-39.

11.

Hartung HP , Gonsette R. , Konig N. , Kwiecinski H. , Guseo A. , Morrissey SP et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-25.

12.

Morrissey SP , Le Page E. , Edan G. Mitoxantrone in the treatment ofl multiple sclerosis. Int MS J 2005; 12: 74-87.

13.

Millefiorini E. , Gasperini C. , Pozzilli C. , D'Andrea F. , Bastianello S. , Trojano M. et al. Randomized placebo-controlled trial ofl mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997; 244: 153-59.

14.

Confavreux C. , Compston DA , Hommes OR , McDonald WI , Thompson AJ EDMUS, a European database flor multiple sclerosis . J Neurol Neurosurg Psychiatry 1992; 55: 671-76.

15.

Poser CM , Paty DW , Scheinberg L. , McDonald WI , Davis FA , Ebers GC et al. New diagnostic criteria flor multiple sclerosis: guidelines flor research protocols. Ann Neurol 1983; 13: 227-31.

16.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.

17.

Debouverie M. , Vandenberghe N. , Morrissey SP , Anxionnat R. , Pittion-Vouyovitch S. , Vespignani H. et al. Predictive parameters ofl mitoxantrone eflflectiveness in the treatment ofl multiple sclerosis. Mult Scler 2004; 10: 407-12.

18.

Tanasescu R. , Debouverie M. , Pittion S. , Anxionnat R. , Vespignani H. Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient. J Neurol 2004; 251: 762-63.

19.

Le Page E. , Leray E. , Taurin G. , Coustans M. , Chaperon J. , Edan G. [ Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis ofl 100 consecutive patients.] Rev Neurol (Paris) 2006; 162: 185-94.

20.

Neuhaus O. , Kieseier BC , Hartung HP Therapeutic role ofl mitoxantrone in multiple sclerosis. Pharmacol Ther 2006; 109: 198-209.

21.

Krapf H. , Morrissey SP , Zenker O. , Zwingers T. , Gonsette R. , Hartung HP Eflflect ofl mitoxantrone on MRI in progressive MS: results ofl the MIMS trial . Neurology 2005; 65: 690-95.